APEPTICO - Innovation in peptide drugs
Meet APEPTICO ...
At the BIO (May 2nd-5th, 2010): Apeptico Forschung und Entwicklung GmbH will attend the BIO International Convention (Chicago). At the BioSquare (February 1st-2nd, 2010) and Bio-Europe Spring (March 8th-10th, 2010): Apeptico Forschung und Entwicklung GmbH will present the company and development products at the BioSquare (Geneva) and Bio-Europe Spring (Barcelona). At the Bio-Europe (November 2nd-4th, 2009): APEPTICO Forschung und Entwicklung GmbH takes part at the Bio-Europe in Vienna, Austria. BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. At the Science4Life Messe (October 22nd, 2009): APEPTICO Forschung und Entwicklung GmbH will present its development compounds at the Science4Life Messe in Frankfurt, Germany. At the CPhI (October 13th-15th, 2009): APEPTICO Forschung und Entwicklung GmbH will attend this year's CPhI in Madrid, Spain. The event covers more than 50,000 sq m of exhibition space, hosting over 1,400 exhibitors and is the market leader for the global pharmaceuticals ingredients industry.
News
APEPTICO's lead molecule AP301 has been validated in the experimental lung transplantation model to prevent ischemia reperfusion injury
23rd February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it's lead molecule AP301 has been validated in the experimental lung transplantation model where intratracheal application of AP301 dramatically improved oxygenation after lung transplantation.
Read more...APEPTICO granted Orphan Drug Designation by FDA for development compound AP301
10th February, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Drug Designation in the USA from the Food and Drug Administration (FDA) for APEPTICO's development compound AP301. AP301 has been granted Orphan Drug Designation in the USA for "prevention of ischemia reperfusion injury in the lung during lung transplantation".
APEPTICO presents its lead product AP301 at the Annual Congress of the European Respiratory Society in Vienna, Austria
08th September, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing a novel peptide-based drug for the treatment of the life threatening disease “Acute Lung Injury” today announced, that it will present its most recent scientific results for APEPTICO’s lead compound AP301 at the Annual Congress of the European Respiratory Society which starts on 12th September 2009 in Vienna, Austria.
APEPTICO granted Orphan Medicinal Product Designation by EMEA for lead product AP301
20th July, 2009, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced that it has received Orphan Medicinal Product Designation in the European Union from the European Medicines Agency (EMEA) for APEPTICO’s lead product AP301 (“Human tumour necrosis factor alpha-derived peptide”) for the “treatment of Acute Lung Injury”.
APEPTICO GmbH erhält Preis anlässlich der Verleihung des “Venture Capital & Private Equity Award Österreichs“
09. Juni 2009, Wien, Österreich: APEPTICO Forschung und Entwicklung GmbH teilt mit, dass das Unternehmen anlässlich der Verleihung des “Venture Capital & Private Equity Award Österreichs“ mit einem Preis ausgezeichnet wurde. Dieser Preis wurde durch den „Styria Börse Express“ und die „Junge Industrie“ verliehen und stellt eine Anerkennung für die kürzlich abgeschlossene Finanzierung des Unternehmens durch Investoren und Österreichische Fördergeber dar.
APEPTICO GmbH closes seed financing round
29th May, 2009, Vienna, Austria: APEPTICO, a biotechnology company developing novel peptide-based drugs, announced completion of a seed financing round. The EUR 1Mio equity financing round was led by The BioScience Ventures Group AG (BSVG, www.bsvg.com, Munich/Germany) and included the participation of the Swiss business angel Dr. Jürg Geigy. Both, BSVG and Dr. Geigy are specialised in early stage investments in the biotech industry. The completion of the financing round entitled APEPTICO to receive a grant of EUR 1.2 Mio from the Austrian Research Promotion Agency (FFG).
Medical breakthrough for treatment of Acute Lung Injury
26th March, 2009, Vienna, Austria: Based on intensive research and comprehensive in-vitro and in-vivo studies APEPTICO Forschung und Entwicklung GmbH, a Vienna development stage biotechnology company, has clarified the mode of action of its development compound AP301. Up to date there exists no approved drug molecule for the treatment of Acute Lung Injury. Up to 100,000 patients in Europe could benefit from the new discovery.